Q-omics provides the consensus-scored ZNF778 profile across patient tissues and cancer cell-line models. ZNF778 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF778 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, ZNF778 RNA expression shows 21,049 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KIRP, and ACC as cancer lineages where ZNF778 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF778 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF778 survival associations across molecular data types. ZNF778 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF778 RNA expression–survival associations across cancer types. High ZNF778 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, HNSC, PAAD, KICH and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF778 RNA expression.
This table summarizes ZNF778 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF778. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF778 shows lower tumor expression in KIRP, KIRC, BRCA and LUSC and higher tumor expression in LIHC and CHOL. The KIRP box plot shows higher ZNF778 RNA expression in normal versus tumor tissue (log2 FC = −0.843, t-test p < 0.001).
This table shows molecular features associated with ZNF778 in patient tissues and cancer cell lines. In patient samples, ZNF778 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF778 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
